Sangamo BioSciences | SGMO - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
Alaunos Therapeutics USD 595K 218K 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Alterity Therapeutics Limited AUD 1.73M 2.77M 2025-12
Amgen USD 24.96B 534M 2026-03
Bayer EUR 33.46B 875M 2026-03
BioCryst Pharmaceuticals USD 195.39M 675K 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Cipla INR 70.14B 7.16B 2026-03
Clal Biotechnology ILS 6.66M 3.75M 2023-12
Compugen USD 22.04M 533K 2026-03
CSL USD 4.61B 207M 2025-12
Gilead Sciences USD 9.48B 2.34B 2026-03
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Grifols EUR 2.37B 156.97M 2025-12
Ionis Pharmaceuticals USD 717M 66M 2026-03
J&J USD 57.72B 3.59B 2026-03
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
Merck USD 26.94B 1.38B 2026-03
Novartis USD 31.37B 4.1B 2026-03
Omeros USD 85.5M 2.28M 2025-06
Pfizer USD 34.35B 2.64B 2026-03
Roche Holding CHF 28B 421M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 30.01B 1.66B 2026-03
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Tectonic Therapeutic USD 12.96M 3.29M 2026-03
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03